A5051545217- Pituitary Gland Disorders and Treatments
- Growth Hormone and Insulin-like Growth Factors
- Neuroendocrine Tumor Research Advances
- Neural dynamics and brain function
- Neuroscience and Neural Engineering
- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Photoreceptor and optogenetics research
- Adrenal and Paraganglionic Tumors
- Myasthenia Gravis and Thymoma
University of Genoa
2013-2025
Ospedale Policlinico San Martino
2019
Neuronal plasticity produces changes in excitability, synaptic transmission, and network architecture response to external stimuli. Network adaptation environmental conditions takes place time scales ranging from few seconds days, modulates the entire dynamics. To study defined long-term experimental protocols, we setup a system that combines optical electrophysiological tools embedded cell incubator. Primary hippocampal neurons transduced with lentiviruses expressing...
Abstract Context Discordant growth hormone (GH) and insulin-like factor-1 (IGF-1) values are frequent in acromegaly. Objective To evaluate the impact of different GH cutoffs on discordance rate. investigate whether mean consecutive measurements impacts rate when matched to last available IGF-1 value. Design Retrospective study. Setting Referral center for pituitary diseases. Patients Ninety acromegaly patients with at least 3 evaluations using same assay laboratory (median follow-up 13...
First-generation somatostatin receptor ligands (fg-SRLs), such as octreotide (OCT), represent the first-line medical therapy in acromegaly. Fg-SRLs show a preferential binding affinity for subtype-2 (SST2), while second-generation ligand, pasireotide (PAS), has high multiple SSTs (SST5 > SST2 SST3 SST1). Whether PAS acts via somatotroph tumors, or through other (e.g., SST5), is matter of debate. In this light, combined treatment OCT+PAS could result additive/synergistic effects. We...
Abstract Context Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT). Objective This was a head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion primary cultures of GH- GH/prolactin (PRL)-secreting tumors; we also investigated the role (SST) dopamine type 2 (D2R) expression. Methods We evaluated antisecretory effect CAB, together with mRNA expression, 23 tumor...
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | 1479-6848 (online)
Abstract Immunohistochemistry of somatostatin receptor subtype 2 (SSTR2) can predict response to first-generation ligands (fg-SRLs) in acromegaly. Recently, we validated an open-source digital image analysis (DIA) quantify SSTR2 expression. We aimed validate the DIA also on SSTR5 a new cohort GH-secreting pituitary tumors, with immunohistochemistry performed different laboratory, and correlate fg-SRL SSTs were assessed 42 using semi-quantitative immunoreactivity score (IRS) by use...